查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1819986

2025-2033年经前症候群治疗市场报告（依药物类型、种类、配销通路和地区）

Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球经前症候群治疗市场规模达14.43亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到19.2亿美元，2025-2033年期间的复合年增长率（CAGR）为3.2%。市场成长的驱动力包括：精准医疗日益受到重视，精准医疗能够改善患者预后并提高治疗效率；医疗保健支出不断增长，从而改善了医疗服务的可及性并扩大了治疗选择；以及女性劳动力参与率的提高。

经前症候群治疗市场趋势：

精准医疗日益受到关注

根据 IMARC 集团的报告，全球精准医疗市场规模在 2023 年将达到 752 亿美元。精准医疗可以根据患者的基因特征、荷尔蒙状态和症状等特征提供量身定制的医疗干预措施。就经前症候群 (PMS) 而言，其症状和严重程度因人而异，个人化治疗方案可以提供更有针对性和更有效的治疗。此外，与 PMS 相关的遗传因素或生物标记有助于为每位患者量身定制最有效的治疗方案。这可以改善治疗效果，减少治疗方案的反覆试验。除此之外，透过根据患者的基因或生理特征来匹配治疗方案来选择不太可能引起不良反应的药物，正在扩大市场成长。

医疗支出不断上涨

随着医疗保健支出的增加，越来越多的人，包括饱受经前症候群 (PMS) 困扰的女性，能够寻求医疗帮助，包括初级保健医生、妇科医生和其他能够对 PMS 进行适当诊断和治疗的从业人员。此外，高额医疗保健支出通常与更多 PMS 治疗方案的可近性相关，这些方案包括荷尔蒙疗法、抗忧郁药物等药物治疗，以及认知行为疗法或生活方式改变等非药物疗法。高额医疗保健支出为研发活动创造了更多机会，有助于找到更好的 PMS 疗法。根据美国医疗保险和医疗补助服务中心 (CMS) 网站 2024 年更新的内容，医疗保健支出占 GDP 的比重预计将从 2022 年的 17.3% 增长到 2032 年的 19.7%。

提高女性劳动参与率

根据世界银行的数据，2023年全球女性劳动参与率为49%。随着越来越多的女性进入职场，经前症候群（PMS）的经济影响日益突出。由于其症状，PMS对工作效率、出勤率和绩效构成威胁。在认识到这些影响后，雇主和医疗保健提供者更有动力寻找有效的治疗方法，以减少PMS对工作场所造成的干扰。此外，企业正在投资工作场所健康计划，其中包括针对PMS等生殖健康问题的支援。这些计划提供治疗、根据症状日期灵活安排工作时间以及教育资源，所有这些都有助于提高公众对PMS现有治疗方法的认识和使用。

经前症候群治疗市场区隔：

依毒品类型分类：

  • 止痛药
  • 抗忧郁药
  • 口服避孕药和卵巢抑制剂
  • 其他的

镇痛药占大部分市场份额

经前症候群是指许多女性在月经週期前出现的一系列生理和心理症状，例如腹痛、头痛和肌肉疼痛。止痛药因其能快速缓解这些症状而广受青睐，成为许多寻求在月经期间立即获得舒适感的女性的首选。此外，人们越来越意识到镇痛药在控制疼痛方面的功效，这推动了经前症候群治疗市场对止痛药的需求。

按类型分列：

  • 处方
  • 在柜檯

场外交易占据产业最大份额

用于治疗经前症候群 (PMS) 的非处方 (OTC) 产品包括止痛药、利尿剂以及钙和镁等其他补充剂，无需医生处方即可在柜檯购买。这种便利性使女性无需就医即可独立治疗症状。腹胀、痉挛、疲劳和情绪波动正成为经前症候群 (PMS) 导致的严重问题。非处方药可根据不同的症状提供多种解决方案。 OTC 品牌的知名度以及从药局、零售店和线上平台购买这些产品的便利性，促进了市场的成长。

按配销通路细分：

  • 医院药房
  • 药局和零售药房
  • 网上商店

药局和零售药局是主要的细分市场

女性喜欢去药局和药房，因为她们可以买到各种各样的非处方药和补充剂来缓解经前症候群的症状。这确保了患有经前症候群的女性能够以最快的方式获得缓解，而无需处方。其次，药局和零售药局为顾客提供各种品牌和形式的产品，可以帮助她们根据自己的需求和症状选择所需的产品。这种多样性提高了个人满意度，并确保人们能够找到符合其特定需求的产品。

按地区划分：

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

北美领先市场，占据经前症候群治疗市场最大份额

该报告还对所有主要区域市场进行了全面分析，包括北美（美国和加拿大）；亚太地区（中国、日本、印度、韩国、澳洲、印尼等）；欧洲（德国、法国、英国、义大利、西班牙、俄罗斯等）；拉丁美洲（巴西、墨西哥等）；以及中东和非洲。报告指出，北美是经前症候群治疗最大的区域市场。

根据加拿大卫生资讯研究所网站发布的一篇文章，加拿大的医疗保健支出在2023年达到3,440亿美元。随着医疗保健支出的不断增长，用于女性健康（包括经前症候群）的专业医疗保健服务和资源也相应增加。这包括改善了获得能够有效诊断和治疗经前症候群的医疗保健专业人员的机会，从而提高了患者对该疾病的认识和认知。此外，北美的经前症候群发生率很高，这促使对有效治疗方案的需求庞大。此外，该地区经济强劲，医疗服务和药物的可负担性更高，进一步推动了市场成长。

（请注意，这只是关键参与者的部分名单，完整名单在报告中提供。）

  • 主要参与者正在开发和推出用于管理经前症候群 (PMS) 症状的新药物和疗法，拓展患者的治疗选择。他们进行研究并参与临床试验，以便更好地理解PMS的机制、验证疗效并探索新的治疗方法。此外，许多公司专注于个人化医疗方法，根据患者的个别特征量身订做治疗方案，从而改善治疗效果和患者满意度。主要参与者参与宣传活动，以提高人们对PMS的认识，提高诊断率，并向医疗保健提供者和患者宣传可用的治疗方案。他们专注于整合数位健康技术，例如用于症状追踪的应用程式、穿戴式装置和远距医疗解决方案，以增强患者护理和治疗效果。例如，2024年，Samphire Neuroscience新创公司筹集了230万美元，利用神经科技穿戴装置来应对PMS和经痛。

本报告回答的关键问题

  • 2024 年全球经前症候群治疗市场规模是多少
  • 2025-2033年全球经前症候群治疗市场的预期成长率是多少
  • 推动全球经前症候群治疗市场的关键因素有哪些
  • COVID-19 对全球经前症候群治疗市场有何影响
  • 根据药物类型，全球经前症候群治疗市场如何划分
  • 全球经前症候群治疗市场按类型划分如何
  • 根据配销通路，全球经前症候群治疗市场如何分布
  • 全球经前症候群治疗市场的主要区域有哪些
  • 全球经前症候群治疗市场的主要参与者/公司有哪些

本报告回答的关键问题

  • 2024年全球经前症候群治疗市场规模？ 2025-2033年全球经前症候群治疗市场的预期成长率是多少？
  • 推动全球经前症候群治疗市场的关键因素有哪些？
  • COVID-19 对全球经前症候群治疗市场有何影响？
  • 根据药物类型，全球经前症候群治疗市场是如何分布的？
  • 全球经前症候群治疗市场按类型划分是怎样的？
  • 根据配销通路，全球经前症候群治疗市场如何分布？
  • 全球经前症候群治疗市场的主要地区有哪些？
  • 全球经前症候群治疗市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球经前症候群治疗市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依药物类型

  • 止痛药
  • 抗忧郁药
  • 口服避孕药和卵巢抑制剂
  • 其他的

第七章：市场区隔：依类型

  • 处方
  • 在柜檯

第八章：市场区隔：按配销通路

  • 医院药房
  • 药局和零售药房
  • 网上商店

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AbbVie Inc.
    • BASF SE
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd
    • Eli Lilly and Company
    • GlaxoSmithKline Plc.
    • H. Lundbeck A/S
    • Pfizer Inc.
    • SHIONOGI & Co. Ltd.
Product Code: SR112025A4284

The global premenstrual syndrome treatment market size reached USD 1,443 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,920 Million by 2033, exhibiting a growth rate (CAGR) of 3.2% during 2025-2033. The market is driven by the growing focus on precision medicine, as it enhances patient outcomes and treatment efficiency, rising healthcare spending, which improves access to care and expands treatment options, and increasing female workforce participation.

Premenstrual Syndrome Treatment Market Trends:

Growing focus on precision medicine

As per the IMARC Group's report, the global precision medicine market reached US$ 75.2 Billion in 2023. Precision medicine can deliver medical interventions that are tailored as per patient characteristics including genetic profile, hormone status, and symptoms. In the context of PMS, it can vary widely in terms of symptoms and severity among individuals, personalized approaches allow for more targeted and effective treatments. Furthermore, genetic factors or biomarkers that are linked to PMS help in tailoring treatment options to be most effective for each patient. This is leading to improved outcomes and lesser trial and error in treatment options. Apart from this, by selecting medications that are less likely to cause an adverse reaction by matching patients with treatments based on their genetic or physiological profiles is expanding the market growth.

Rising healthcare spending

As healthcare expenditure is increasing, more people, including women troubled with PMS, are able to seek medical help, including primary care physicians, gynecologists and other practitioners who may diagnose and treat PMS appropriately. In addition, high healthcare spending often found to be associated with higher access to other treatment options of PMS, which includes pharmacological treatment like hormonal therapies, antidepressants, and non-pharmacological therapies like cognitive behavioral therapy or lifestyle modifications. High healthcare expenditure is creating more opportunities for R&D activities that can help find better PMS therapies. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the healthcare spending share of GDP is forecasted to grow from 17.3% in 2022 to 19.7% in 2032.

Increasing female workforce participation

As per the World Bank, female labor force participation rates were 49% worldwide in 2023. As more women are entering the workforce, the economic implications of PMS are becoming more apparent. This poses a threat to productivity, attendance and performance at work due to its symptoms. Recognizing these impacts, employers and healthcare providers are more motivated to find effective treatments that can help reduce the workplace disruptions caused by PMS. In addition, companies are investing in workplace wellness programs that include support for reproductive health issues like PMS. These programs offer access to therapies, flexible scheduling around symptomatic days, and educational resources, all of which increase awareness and use of available PMS treatments.

Premenstrual Syndrome Treatment Market Segmentation:

Breakup by Drug Type:

  • Analgesics
  • Antidepressants
  • Oral Contraceptives and Ovarian Suppression Agents
  • Others

Analgesics accounts for the majority of the market share

Premenstrual syndrome refers to several symptoms that are physical and psychological in nature and which affect many women prior to menstrual cycles, such as abdominal pain, headaches, and muscular pain. Analgesics are widely preferred as they provide quick relief from these symptoms, making them a go-to choose for many women looking immediate comfort during their menstrual cycles. In addition, people are getting aware about their efficiency in controlling pain, which is driving the demand for analgesics in the PMS treatment market.

Breakup by Type:

  • Prescription
  • Over-the-Counter

Over-the-counter holds the largest share of the industry

Over-the-counter (OTC) products for PMS include pain relievers, diuretics, and other supplements like calcium and magnesium that one can be purchased on the counter without the prescription of doctor. This accessibility allows women treat symptoms independently without having to see a doctor. Bloating, cramping, fatigue, and mood swings are becoming serious problems as a result of PMS. OTC medicines offer numerous solutions to these issues as per different symptoms. The familiarity of OTC brands and the ease of purchasing these products from pharmacies, retail stores, and online platforms is contributing to the market growth.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Stores

Drugs stores and retail pharmacies represent the leading market segment

Women are preferring drug stores and pharmacies as they can get a wide range of OTC medications and supplements to alleviate PMS symptoms. This ensures that those women suffering from PMS can get relief in the quickest way possible without the need for a prescription. . Secondly, drug stores and retail pharmacies offer customers a wide diversity of brands and forms of products which can help them select the required products according to their needs and symptoms. This variety enhances individual satisfaction and ensures that people can find products tailored as per their specific needs.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest premenstrual syndrome treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for premenstrual syndrome treatment.

As per an article published on the website of Canadian Institute for Health Information, Canada health care spending reached $344 billion in 2023. As healthcare expenditures is rising, there is a corresponding increase in the availability of specialized healthcare services and resources dedicated to the health of women, including PMS. This includes improved access to healthcare professionals who can diagnose and treat PMS effectively, leading to greater awareness and recognition of the condition among patients. Moreover, North America has a high prevalence of PMS cases, which prompts a significant demand for effective treatment solutions. In addition, the strong economy of the region, leading to the greater affordability of healthcare services and medications, further driving the market growth.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

  • Key players are developing and introducing new medications and treatments for managing PMS symptoms, expanding treatment choices for patients. They are conducting research and participating in clinical trials to better understand PMS mechanisms, validate treatment efficacy, and explore new therapeutic approaches. Moreover, many companies are focusing on personalized medicine approaches to tailor treatments based on individual patient characteristics, improving treatment outcomes and patient satisfaction. Key players are involved in advocacy efforts to raise awareness about PMS, improve diagnosis rates, and educate healthcare providers and patients about available treatment options. They are focusing on integrating digital health technologies, such as apps for symptom tracking, wearable devices, and telemedicine solutions, to enhance patient care and treatment outcome. For instance, in 2024, Samphire Neuroscience startup raised $2.3M to tackle PMS and period pain using neurotechnology wearable.

Key Questions Answered in This Report

  • 1.What was the size of the global premenstrual syndrome treatment market in 2024?
  • 2.What is the expected growth rate of the global premenstrual syndrome treatment market during 2025-2033?
  • 3.What are the key factors driving the global premenstrual syndrome treatment market?
  • 4.What has been the impact of COVID-19 on the global premenstrual syndrome treatment market?
  • 5.What is the breakup of the global premenstrual syndrome treatment market based on the drug type?
  • 6.What is the breakup of the global premenstrual syndrome treatment market based on the type?
  • 7.What is the breakup of the global premenstrual syndrome treatment market based on the distribution channel?
  • 8.What are the key regions in the global premenstrual syndrome treatment market?
  • 9.Who are the key players/companies in the global premenstrual syndrome treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Premenstrual Syndrome Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Analgesics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Antidepressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oral Contraceptives and Ovarian Suppression Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Prescription
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Over-the-Counter
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 BASF SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Dr. Reddy's Laboratories Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 GlaxoSmithKline Plc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 H. Lundbeck A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SHIONOGI & Co. Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Premenstrual Syndrome Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019-2024
  • Figure 3: Global: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 4: Global: Premenstrual Syndrome Treatment Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Premenstrual Syndrome Treatment Market: Breakup by Type (in %), 2024
  • Figure 6: Global: Premenstrual Syndrome Treatment Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Premenstrual Syndrome Treatment Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Premenstrual Syndrome Treatment (Analgesics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Premenstrual Syndrome Treatment (Analgesics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Premenstrual Syndrome Treatment (Antidepressants) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Premenstrual Syndrome Treatment (Antidepressants) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Premenstrual Syndrome Treatment (Prescription) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Premenstrual Syndrome Treatment (Prescription) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Premenstrual Syndrome Treatment (Online Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Premenstrual Syndrome Treatment (Online Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: North America: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: North America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: United States: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: United States: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Canada: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Canada: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Asia-Pacific: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Asia-Pacific: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: China: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: China: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Japan: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Japan: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: India: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: India: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: South Korea: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: South Korea: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Australia: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Australia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Indonesia: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Indonesia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Europe: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Europe: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Germany: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Germany: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: France: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: France: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United Kingdom: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United Kingdom: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Italy: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Italy: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Spain: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Spain: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Russia: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Russia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Latin America: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Latin America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Brazil: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Brazil: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Mexico: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Mexico: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Middle East and Africa: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Middle East and Africa: Premenstrual Syndrome Treatment Market: Breakup by Country (in %), 2024
  • Figure 74: Middle East and Africa: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Premenstrual Syndrome Treatment Industry: SWOT Analysis
  • Figure 76: Global: Premenstrual Syndrome Treatment Industry: Value Chain Analysis
  • Figure 77: Global: Premenstrual Syndrome Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Premenstrual Syndrome Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 3: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 4: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 5: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Premenstrual Syndrome Treatment Market: Competitive Structure
  • Table 7: Global: Premenstrual Syndrome Treatment Market: Key Players